Implications and mechanisms of O-GlcNAcylation in cancer therapy resistance

O-linked-N-acetylglucosaminylation (O-GlcNAcylation), one of the protein post-translational modifications, is the process of adding O-linked-β-D-N-acetylglucosaminylation (O-GlcNAc) to serine and threonine residues of proteins. O-GlcNAcylation regulates various fundamental cell biological processes, including gene transcription, signal transduction, and cellular metabolism.

Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

The Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) is Italy’s first cooperative oncology research group, evolving to conduct academic clinical trials since 1985. With 167 publications and collaborations with national and international partners, GOIRC has significantly impacted clinical practices.

Four pathogenic variants co-occurring in a MINAS early-onset breast cancer

Multilocus Inherited Neoplasia Allele Syndrome (MINAS) is a condition defined by the presence of germline pathogenic variants in more than one Cancer Susceptibility Gene (CSG). MINAS is still underreported in the literature and public databases. Since MINAS-related phenotypes are difficult to predict, case descriptions may contribute to risk assessment, treatment, and personalized surveillance for proband and relatives.

Evolving perspectives: Exploring the role of artificial intelligence between clinical practice and health pastoral care

This article analyses the integration of artificial intelligence (AI) in health pastoral care, emphasizing the synergy between technology and spirituality. This paper discusses possible AI applications, highlighting the importance of ethical implementation that respects human interactions. Ethical issues like privacy and empathy are examined, as well as the potential of AI in facilitating collaboration between healthcare professionals and pastoral workers. Finally, it calls for a debate on the responsible use of AI in care contexts.

European Cancer Organisation Essential Requirements for Quality Cancer Care for ovarian cancer: Focus on the multidisciplinary team

European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC) are written by experts representing all disciplines involved in cancer care in Europe. They give patients, health professionals, managers and policymakers a guide to essential care. Here, the essential requirements to treat ovarian cancer patients are described.

Volume 110 Issue 6, December 2024

Read the latest issue. It contains the following articles: Hot topics in genitourinary_cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy.
Proton therapy for pediatric malignancies: Indications and challenges focusing on the oncological landscape
Enhanced patient journey associated with improved overall survival in colon cancer patients: A study by the Ligurian Oncology Network
Practices and views about palliative care at the end of life: A survey of oncologists from the Italian region of Liguria
Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer
Self-perceived attitudes of Italian oncology nurses towards clinical trial involvement: A cohort observational study.
Fat necrosis after accelerated partial breast irradiation or hypofractionated whole breast irradiation: A case-control study.
High throughput sequencing reveals alterations in B cell receptor repertoires associated with the progression of hepatic cirrhosis to hepatocellular carcinoma
Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase lI clinical study_(NCT03822936)
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making